No Data
No Data
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating
Further Weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) Drops 12% This Week, Taking Five-year Losses to 54%
Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35
EyePoint Pharmaceuticals Announces Board Changes and New Appointments
Express News | EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15